SCHEMBL826145

SCHEMBL826145

CONC(=O)c1ccc(-c2ccc3nc(N)nc(OC(C)(C)C)c3n2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK2 Q9HBH9 6/20 0.36
MKNK1 Q9BUB5 5/20 0.34
MAP4K4 O95819 4/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
CSNK2A2 P19784 1/20 0.32
CSNK2B P67870 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 1/20 0.32
MCL1 Q07820 1/20 0.32
TLR9 Q9NR96 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
PARP1 P09874 1/20 0.32
MAPK13 O15264 1/20 0.32
MAPK12 P53778 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL825895 0.90 MKNK2 (0.34) MKNK2MKNK1MAP4K4PDE4APDE4B
SCHEMBL826277 0.89 JAK2 (0.39) MKNK2MKNK1MAP4K4MAPT
SCHEMBL825747 0.88 MKNK2 (0.45) MKNK2MKNK1MAP4K4KDM4EMAPT
SCHEMBL826358 0.85 MKNK1 (0.45) MKNK2MKNK1MAP4K4MEN1KMT2A
SCHEMBL823724 0.85 MKNK2 (0.38) MKNK2MKNK1MAP4K4PDE4APDE4B
SCHEMBL823761 0.85 MKNK2 (0.38) MKNK2MKNK1MAP4K4MAPT
SCHEMBL826110 0.85 HDAC4 (0.41) MKNK2MKNK1KDM4EMEN1MAPT
SCHEMBL823734 0.84 MKNK2 (0.41) MKNK2MKNK1MAP4K4PDE4APDE4B
SCHEMBL825655 0.84 MKNK1 (0.47) MKNK2MKNK1MAP4K4KMT2AHDAC6
SCHEMBL825764 0.84 MKNK1 (0.41) MKNK2MKNK1KDM4EMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC (US) 2009-12-31 US claimed
US-8143394-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2012-03-27 US disclosed
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC (US) 2009-12-31 US disclosed
WO-2008077649-A1 PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTONS GILEAD SCIENCES, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS PNPO, DPYD, PLPBP MKNK2 3173/4885MKNK1 3271/4885MAP4K4 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.